SEARCH RESULT

Total Matching Records found : 110

SC’s novartis judgement renews focus on accessible medicine

The recent Supreme Court judgment dismissing pharma giant novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...

More »

HIV, cancer patients seek access to affordable medicines-Aarti Dhar

-The Hindu     Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...

More »

Indian patent rulings may face legal heat internationally -Soma Das

-The Economic Times The recent patent rulings in India may get frequently challenged in international courts if the government yields to the European Union's demand of including matters related to intellectual property in the investors-state dispute mechanism in their proposed trade pact, health activist groups have warned. An investor-state dispute resolution mechanism typically allows foreign investors to sue countries for compensation if national laws, policies, court rulings of the country infringe upon...

More »

New mechanism: price of cancer drugs set to fall -Himani Chandna Gurtoo

-The Hindustan Times Cancer drugs will cost almost 25% less if the regulator implements a new formula that calls for a price cap. The price regulator National Pharmaceutical Pricing Authority (NPPA) is considering a pricing mechanism similar to the one for insulin products - which has brought down prices by up to 40% - for 33 cancer drugs, most of them generics. Basically, the lowest price from the list of drugs in a...

More »

Most big patented drugs skip India -Rupali Mukherjee

-The Times of India Big pharma may be crying hoarse over India's "weak'' intellectual property environment, but over the past five years or so, they have introduced only a handful of their patented blockbusters in the country. That's not all. The contribution of patented drugs in the Rs 72,000-crore pharma retail market is not even 1%, indicating that multinationals have been traditionally slow and have a poor track record in introducing...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close